Last reviewed · How we verify

NCT05790902

COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI

Completed Phase 1 Last updated 30 March 2023
What this trial tests

Phase 1 trial testing Silodosin in Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi in 142 participants. Completed in 28 February 2023.

Timeline
1 September 2022
Primary endpoint
28 February 2023
28 February 2023

Quick facts

Lead sponsorArmed Forces Institute of Urology, Rawalpindi
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment142
Start date1 September 2022
Primary completion28 February 2023
Estimated completion28 February 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Armed Forces Institute of Urology, Rawalpindi

Who can join

Adults 18 to 55, any sex, with Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

to compare efficacy and safety of Silodosin and Tamsulosin in Medical expulsive therapy of Distal Ureteric Calculi.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Silodosin

Trials testing the same drug.

Other Armed Forces Institute of Urology, Rawalpindi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05790902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing